Apollomics (APLM) investor relations material

Company overview and business model

• Clinical-stage biotechnology company focused on developing oncology therapies for difficult-to-treat and treatment-resistant cancers, with a pipeline of three active clinical-stage product candidates.

• Lead candidate, vebreltinib, is a selective c-Met inhibitor targeting cancers with MET gene alterations, with conditional approvals in China and orphan drug designation in the U.S.

• Operations are conducted through U.S. headquarters and a wholly-owned PRC subsidiary, with additional subsidiaries in Australia and Hong Kong; structured as a Cayman Islands holding company.

• Employs a biomarker-driven diagnostic approach and pursues both monotherapies and combination therapies to improve cancer treatment outcomes.

• No variable interest entities (VIEs) are used in the corporate structure, and there are no current plans to establish any VIEs in China.

Financial performance and metrics

• As of June 30, 2025, cash and cash equivalents totaled $2.1 million, increasing to $6.2 million after the September 2025 PIPE financing.

• Net assets improved from a deficit of $4.4 million to $0.3 million post-PIPE.

• Accumulated losses stood at $713.4 million, with share capital and share premium totaling $670.4 million and $42.4 million, respectively, after adjustments.

• No dividends or distributions have been made to date; cash transfers have primarily been from the holding company to subsidiaries for working capital.

Use of proceeds and capital allocation

• All proceeds from the sale of Class A Ordinary Shares in this offering will go to the selling securityholders; the company will not receive any proceeds.

• The company will bear registration-related expenses, while selling securityholders are responsible for their own selling expenses.